PDUFA VI: NORD Wants Reviewers To Be More Accessible
Executive Summary
As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.
You may also be interested in...
US FDA Planning Another Patient Group To Boost Involvement
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.
Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?
Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.